The promises and perils of circulating tumor DNA for monitoring immunotherapy response in non-small cell lung cancer

There has been a rapid expansion of immunotherapy options for non-small cell lung cancer (NSCLC) over the past two decades, particularly with the advent of immune checkpoint inhibitors. Despite the emerging role of immunotherapy in adjuvant and neoadjuvant settings though, relatively few patients wi...

Full description

Saved in:
Bibliographic Details
Main Authors: Brandon Joseph Hebert, James Bradley
Format: Article
Language:English
Published: Open Exploration Publishing Inc. 2024-11-01
Series:Exploration of Targeted Anti-tumor Therapy
Subjects:
Online Access:https://www.explorationpub.com/Journals/etat/Article/1002280
Tags: Add Tag
No Tags, Be the first to tag this record!